NALBUPHINE HYDROCHLORIDE

Post-LOE

nalbuphine hydrochloride

Pfizer

ANDAINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSSOLUTION

Approved

Feb 1989

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

NALBUPHINE HYDROCHLORIDE (nalbuphine hydrochloride) by Pfizer is mechanism of action nalbuphine is an agonist at kappa opioid receptors and an antagonist at mu opioid receptors. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 1989.

Drug data last refreshed 20h ago

Mechanism of Action

Mechanism of Action Nalbuphine is an agonist at kappa opioid receptors and an antagonist at mu opioid receptors.

Indications (2)

pain severe enough to require an opioid analgesic for which alternative treatments are inadequate

Clinical Trials (1)

NCT06785571Phase 2/3Recruiting

The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial

Started Aug 2023

204 enrolled

Respiratory Insufficiency

Worked on NALBUPHINE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.